New Data From Phase 3 Trial Further Validate Prognostic Value Of Veracyte's Decipher Prostate Genomic Classifier
Portfolio Pulse from Benzinga Newsdesk
Veracyte, Inc. (NASDAQ:VCYT) announced new data from a phase 3 trial that reinforces the value of the Decipher Prostate Genomic Classifier in helping physicians make more informed treatment decisions for their patients with prostate cancer. The findings were presented at the 2023 American Society for Radiation Oncology (ASTRO) Annual Meeting. A second study presented at the meeting revealed minimal to moderate risk-score correlation between three commercially available genomic classifiers, suggesting that the level of evidence supporting each genomic test should drive utilization.
October 04, 2023 | 8:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Veracyte's Decipher Prostate Genomic Classifier has been further validated by new data from a phase 3 trial, reinforcing its value in aiding physicians in making informed treatment decisions for prostate cancer patients.
The new data from the phase 3 trial further validates the Decipher Prostate Genomic Classifier's ability to accurately categorize risk for patients with clinically high-risk disease, which can inform appropriate treatment. This positive news could potentially increase the utilization of Veracyte's product, leading to potential growth in revenues and a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100